These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24261554)

  • 21. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
    Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
    Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
    Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
    Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
    Mikaelsson M; Oswaldsson U
    Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
    Barrowcliffe TW; Raut S; Sands D; Hubbard AR
    Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
    Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-stage vs. chromogenic assays in haemophilia A.
    Potgieter JJ; Damgaard M; Hillarp A
    Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study.
    Cinotti S; Longo G; Messori A; Morfini M; Blomback M; Schimpf K; Schumacher K; Kjellman H; Novakova-Banet A; Delvos U
    Thromb Res; 1991 Feb; 61(4):385-93. PubMed ID: 1905848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
    Leksa NC; Chiu PL; Bou-Assaf GM; Quan C; Liu Z; Goodman AB; Chambers MG; Tsutakawa SE; Hammel M; Peters RT; Walz T; Kulman JD
    J Thromb Haemost; 2017 Jun; 15(6):1167-1179. PubMed ID: 28397397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant factor VIII Fc for the treatment of haemophilia A.
    Hermans C; Mancuso ME; Nolan B; Pasi KJ
    Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
    Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
    Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor VIII assay mimicking in vivo coagulation conditions.
    Kusch M; Grundmann C; Keitel S; König H
    Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.